

To: [redacted] @minvws.nl]; [redacted] [redacted] @minvws.nl]
Cc: [redacted] @minvws.nl]
From: [redacted]
Sent: Mon 3/22/2021 8:08:43 AM
Subject: FW: AstraZeneca - AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis
Received: Mon 3/22/2021 8:08:56 AM

Beste [redacted]

Jullie stonden al in Cc maar hierbij ook even direct aan jullie het persbericht over de US resultaten met het AstraZeneca/Oxford vaccin.

Hierbij de link naar het persbericht: <https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html>

Er is een 79% vaccin efficacy gevonden in voorkomen van symptomatische COVID-19. In de 65+ groep was de vaccin efficacy 80%.

Er was een 100% efficacy tegen hospitalisatie en ernstige ziekte.


Met vriendelijke groeten,

[redacted signature block]

AstraZeneca BV
Bezoekadres: Prinses Beatrixlaan 582, 2595 BM Den Haag
T: +31 (0)79 [redacted] M: +31 (0)6 [redacted]
[redacted] @astrazeneca.com
www.astrazeneca.nl

Please consider the environment before printing this e-mail

This e-mail is intended solely for the use of the addressee and is not meant for distribution or disclosure outside AstraZeneca. The information in this e-mail may be personal or confidential. Any views or opinions presented do not necessarily represent those of AstraZeneca. Should you receive this message by mistake, please notify the sender immediately and delete this e-mail from your system without opening the attachment.



Dubbel

5.1.2e

5.1.2e

5.1.2e

5.1.2e

Dubbel

3 - 3

Dubbel